# Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection

> **NCT03487848** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 5 (actual)

## Conditions studied

- Hepatitis C
- Chronic Hepatitis

## Interventions

- **DRUG:** Daclatasvir
- **DRUG:** Sofosbuvir

## Key facts

- **NCT ID:** NCT03487848
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-25
- **Primary completion:** 2018-10-18
- **Final completion:** 2020-09-17
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2021-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03487848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03487848, "Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03487848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*